T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
Li W, Ren S, Li J, Li A, Fan L, Li X, Zhao C, He Y, Gao G, Chen X, Li S, Shi J, Zhou C, Fei K, Schmid-Bindert G.
Li W, et al. Among authors: li s, li j, li x, li a.
Lung Cancer. 2014 Jun;84(3):295-300. doi: 10.1016/j.lungcan.2014.03.011. Epub 2014 Mar 15.
Lung Cancer. 2014.
PMID: 24685306